A Phase 2 interventional study of Rimonabant in Spinal Cord Injuries, sponsored by Hospital Nacional de Parapléjicos de Toledo. Status unknown at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-21.
Sponsored by Hospital Nacional de Parapléjicos de Toledo · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Spinal Cord Injuries with a site in Spain — 12 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.
Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 6th largest by planned enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2022, is one of 6 in phase 2, and was the 41st registered.
2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.
Browse Spinal Cord Injuries studies →12 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:
ABLE Human Motion S.L. · Sites in Spain
Ages up to 17
ABLE Human Motion S.L. · Sites in Spain
Ages 18–70
Technophage, SA · Sites in Spain
Ages 18–65
MarsiBionics · Sites in Spain
Ages 3–14
Institut Guttmann · Sites in Spain
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 2 · Phase 4 2
First in 2005; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 24 across 1,635 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 30 across the 55 interventional studies, 51 across the 4 observational. Of the 40 that completed or were terminated, 5 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 59 have an industry lead sponsor. The 10 most frequent:
Hospital Nacional de Parapléjicos de Toledo is the lead sponsor of 6 studies on the registry; none are open to participants now.
Hospital Nacional de Parapléjicos de Toledo has 6 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
4 of the studies in Spinal Cord Injuries with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06677229Technophage, SAPhase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury | 2026-12 |
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
| NCT05142943University of ValenciaEffectiveness of Virtual Bodily Illusion Intervention in Upper Limb Motor Function in People With Incomplete Spinal Cord Injury. | 2026-12-31 |
| NCT07036107ABLE Human Motion S.L.A Trial on the Clinical and Socioeconomic Impact of Wearable Exoskeletons for Spinal Cord Injury Rehabilitation in the Spanish Healthcare System | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Spinal Cord Injuries with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo for the same period. Objective is to improve walking abilities of spinal cord injury individuals (incomplete lesions) and demonstrate that it is a safe treatment in spinal cord injury population.
This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo for the same period.
Main goal are to test safety and efficacy (impairment of walking abilities teste with the 6 min walking test) of Rimonabant in a specific population (incomplete spinal cord injury).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rimonabant 5mg
Drug: Rimonabant
Placebo
Drug: Rimonabant
Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
Also known as: Placebo
Adverse Events (Safety)
Number of AE
Time frame: 120 days
Biochemical and urine analysis (safety)
Number of participants with clinically significant abnormal laboratory tests results
Time frame: 120 days
ECG (safety)
Number of participants with clinically significant abnormal ECG readings
Time frame: 120 days
Hospital Anxiety and Depression Scale (HAD) (safety
Range 0-21(higher values more severe)
Time frame: 120 days
Modified Ashworth Scale (safety)
Range 0-4 (higher values more severe)
Time frame: 90 days
Penn Scale (safety)
Range 0-4 (higher values more severe)
Time frame: 90 days
Pain numeric rating scale (safety)
Range 0-10 (higher values more severe)
Time frame: 90 days
Questionnaire of falls (safety)
Number of falls
Time frame: 120 days
6 min walking test (efficacy)
6 min walking test (meters and number of stops are reported)
Time frame: 90 days
10 m test (efficacy)
Time to walk 10 m (no stops are allowed)
Time frame: 90 days
Borg Scale (efficacy)
Borg Scale punctuation after 6 min waking test. Range 0-10.
Time frame: 90 days
Motor Score (efficacy)
Motor Score (ISNCSCI). Range 0-20 (higher values less severe)
Time frame: 90 days
Fatigue Severity Scale (FSS) (Efficacy)
FSS puntuación. Range 0-7 (higher values more severe)
Time frame: 90 days
Patient global impression of changes (PGIC) (efficacy)
PGIG score. Range 1-7 (higher values indicate worsening)
Time frame: 90 days
European Quality of Life -5 Dimensions (EQ-5D) (efficacy)
EQ-5D questionnaires have 5 dimensions: "Mobility", "Human Autonomy," "Current Activities", "Pain / Discomfort", "Anxiety / Depression" and all dimensions are described by 3 problem levels corresponding to patient response choices (higher values worst). A quality-of-life score is obtained according to the answers to the questionnaires (algorithm to calculate the score in euroqol.org). The maximum score is 1 that indicates excellent quality of life (range for Spanish version 0.5-1).
Time frame: 90 days
Health state visual analogically scale (efficacy)
Range 0-100 mm (higher values indicate higher health state )
Time frame: 90 days
Spinal Cord Independence Measures, SCIM (efficacy)
Range 0-100 (higher values indicate higher independence )
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2022; primary completion for Nov 2023, 12 months later.
Of 44 non-industry phase 2 interventional studies under Spinal Cord Injuries, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 64. This study's planned 12 months is below that.
Counting every sponsor, half of 49 studies reached it within 46 months; a quarter within 28 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimonabant
Hospital Nacional de Parapléjicos de Toledo